Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today announced the presentation of research findings for the Company’s novel class of anti-PD-1 antibodies at the Function of the Tumor Microenvironment in Cancer Progression Conference, sponsored by the American Association for Cancer Research (AACR) and taking place in San Diego, CA, from January 7-10, 2016. Enumeral is advancing a novel class of potentially allosteric anti-PD-1 antibodies with distinctive properties compared to currently marketed anti-PD-1 antagonists, including a mechanism of action that does not appear to require the disruption of PD-1 interaction with PD-L1.

Enumeral is reporting in a poster presentation at the AACR conference that Enumeral’s anti-PD-1 antibodies can reverse T cell suppression in ex vivo assays by eliciting high levels of T-cell activation as measured by increased secretion of effector cytokines such as interferon gamma and increases in expression of the IL-2 receptor alpha chain, CD25. Further, in an in vivo preclinical model harboring a reconstituted human immune system, Enumeral’s fully humanized anti-PD-1 antibodies exhibited significant anti-tumor efficacy against a human lung adenocarcinoma xenograft.

In addition, Enumeral is presenting a second poster at the AACR conference detailing how Enumeral’s proprietary single-cell immune profiling technology was used to match T cell receptor alpha and beta (TCRα and TCRβ) pair sequences from specified T cells isolated from the tumor of a metastatic melanoma patient and uniquely link them to their functional profiles. In this method, researchers first identified a subset of T cells of interest based on their functional profiles, including surface markers and secreted cytokines, and then isolated each individual T cell for TCR sequencing. Results presented demonstrated this method can be applied to T cells from both blood and solid tissues, enabling the identification of rare or expanded T cell clones.

Enumeral Abstracts at AACR’s 2016 Tumor Microenvironment Special Conference

“Determination of expressed T cell receptor sequences of single human T cells isolated after functional profiling.” Abstract #A14; Poster Session A: Tumor Immunity and Therapies; Thursday, January 7, 2016, from 7:30-9:30 PM Pacific Time.

“Discovery and functional characterization of novel anti-PD-1 antibodies using ex vivo cell-based assays, single-cell immunoprofiling, and in vivo studies in humanized mice.” Abstract #B30; Poster Session B; Friday, January 8, 2016, from 4:00-6:00 PM Pacific Time.

About Enumeral

Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.

Forward Looking Statements Disclosure

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements reflect current beliefs of Enumeral Biomedical Holdings, Inc. (“Enumeral”) with respect to future events and involve known and unknown risks, uncertainties, and other factors affecting operations, market growth, Enumeral’s stock price, services, products and licenses. No assurances can be given regarding the achievement of future results, and although Enumeral believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, actual results may differ from the assumptions underlying the statements that have been made regarding anticipated events. Factors that may cause actual results, performance or achievements, or industry results to differ materially from those contemplated by such forward-looking statements include, among others, the risks that (a) Enumeral’s expectations regarding market acceptance of the Company’s business in general and the Company’s ability to penetrate the antibody discovery and development fields in particular, as well as the timing of such acceptance, (b) Enumeral’s ability to attract and retain management with experience in biotechnology and antibody discovery and similar emerging technologies, (c) the scope, validity and enforceability of Enumeral’s and third party intellectual property rights, (d) Enumeral’s ability to raise capital when needed and on acceptable terms and conditions, (e) Enumeral’s ability to comply with governmental regulation, (f) the intensity of competition, (g) changes in the political and regulatory environment and in business and fiscal conditions in the United States and overseas and (h) general economic conditions.

More detailed information about Enumeral and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in Enumeral’s filings with the Securities and Exchange Commission. Enumeral urges investors and security holders to read those documents free of charge at the Commission’s website at http://www.sec.gov. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, Enumeral undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.